Hybridyne Imaging Technologies Inc. announced it has received FDA clearance for its ProxiScan system. Using planar imaging techniques, the system can be used in imaging the distribution of radionuclides in the human body. It may also be used intra-operatively, on pathological specimens and for endocavity applications if a protective sheath is used. It uses a small cadmium zinc telluride (CZT)-based compact gamma camera developed by the company in collaboration with scientists at Brookhaven National Laboratory. The size enables it to be placed close to the object of interest, reducing the possible radiation does to patients. Additionally, it can deliver high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. This could impact medical applications, especially for the widespread need for better nuclear-medical imaging in cancer diagnostics. When coupled with a suitable radioactive tracer, it has the potential to detect smaller lesions than conventional Anger cameras, said Dr. Youngho Seo, a faculty member at the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Hybridyne develops compact gamma cameras fro imaging radiopharmaceuticals distributed in the body, using solid-state detectors and miniaturized digital circuits for creating new diagnostic tools and treatment capabilities. For more information, visit: www.hybridyneimagingtechnologies.com